This is Part 2 of our interview with Prof. Ernst Hafen, president of MIDATA and professor of Systems Biology at ETH Zurich. In this episode, we focus on the critical challenge of translating academic research into real-world medicine — and what healthcare might look like by 2040.
The Gap Between Academic Research and Clinical Application
Despite billions of dollars invested in biomedical research each year, the vast majority of scientific discoveries never reach patients. The path from a promising laboratory finding to an approved therapy is long, expensive, and fraught with failure. Ernst Hafen discusses the systemic reasons for this gap and what can be done to close it.
Key barriers to translation include:
- Insufficient funding for the "middle stages" between basic research and clinical trials
- Academic incentive structures that reward publications over practical applications
- Regulatory complexity that discourages small teams and startups
- Lack of communication between academic researchers and clinical practitioners
Switzerland's Bio-Technopark Schlieren: A Model for Translation
The Bio-Technopark Schlieren near Zurich serves as an example of how physical infrastructure can foster the translation of academic research into commercial products. By co-locating startups, established companies, and research groups, the technopark creates an ecosystem where ideas can flow more freely from lab bench to market.
Bridging the Valley of Death
The so-called "valley of death" — the gap between basic research funding and commercial investment — remains one of the biggest bottlenecks in drug discovery. Startups play a crucial role in bridging this gap, but they face enormous challenges:
- Funding gaps: Too advanced for academic grants, too early for venture capital
- Talent acquisition: Competing with both academia and large pharma for skilled researchers
- Regulatory navigation: Understanding and meeting regulatory requirements without dedicated teams
- Time pressure: Running out of runway before reaching key milestones
The Role of Technology Transfer Offices
University technology transfer offices (TTOs) are meant to facilitate the commercialization of academic research. However, their effectiveness varies widely. The best TTOs act as true partners, helping researchers navigate IP protection, licensing, and company formation. The worst become bureaucratic bottlenecks that slow down or kill promising ventures.
Challenges in Bringing Personalized Medicine to Patients
Personalized medicine — tailoring treatments to individual patients based on their genetic makeup, lifestyle, and environment — holds enormous promise. But significant challenges remain:
- The cost of comprehensive genomic profiling is dropping but still not universally accessible
- Healthcare systems are built around one-size-fits-all treatment protocols
- Physicians need training and decision-support tools to interpret genomic data
- Reimbursement models have not caught up with personalized approaches
Data-Driven Approaches to Healthcare and Preventive Medicine
Building on the themes from Part 1, Ernst discusses how aggregated citizen health data — collected through cooperatives like MIDATA — can power a shift from reactive to preventive medicine. Instead of waiting for disease to manifest and then treating it, data-driven approaches can identify risk factors early and intervene before symptoms appear.
The Future of Medicine by 2040: P4 Medicine
Ernst envisions a future of medicine organized around four pillars — often called P4 medicine:
- Predictive: Using data and algorithms to forecast disease risk before symptoms appear
- Preventive: Intervening early with lifestyle changes, supplements, or targeted therapies to prevent disease
- Personalized: Tailoring treatment plans to the individual based on their unique biology
- Participatory: Empowering patients and citizens as active partners in their own healthcare
By 2040, the patient who walks into a clinic with an advanced disease will be the exception, not the norm. Data-driven, participatory medicine will catch most conditions early — when they are still preventable or easily treatable.
How Citizen Data Cooperatives Connect to Translational Medicine
The MIDATA cooperative model discussed in Part 1 has direct implications for translation. When citizens contribute their health data to research, they create a resource that can:
- Validate drug targets using real-world population data
- Identify patient subgroups that respond differently to treatments
- Provide post-market safety data at unprecedented scale
- Enable adaptive clinical trial designs powered by continuous data streams
Policy Recommendations for Accelerating Translation
Ernst offers several policy recommendations for governments and institutions seeking to accelerate the translation of research into clinical practice:
- Create dedicated funding mechanisms for translational research
- Reform academic incentive structures to value translational impact alongside publications
- Establish regulatory sandboxes that allow controlled experimentation with new approaches
- Invest in digital infrastructure for health data sharing and interoperability
- Support citizen data cooperatives as a model for ethical, scalable data governance
About Bio2040
There are so many challenges in drug discovery. We are a group of entrepreneurs and scientists who want to improve things.
Subscribe to the Podcast on iTunes
Be in the know and sign up for the newsletter.
Follow Flavio on Twitter here.